Equity Overview
Price & Market Data
Price: $40.50
Daily Change: -$0.61 / 1.51%
Range: $39.95 - $40.94
Market Cap: $7,560,617,984
Volume: 1,114,774
Performance Metrics
1 Week: -1.22%
1 Month: 2.81%
3 Months: 3.76%
6 Months: -14.17%
1 Year: 4.02%
YTD: -7.20%
Company Details
Employees: 534
Sector: Health technology
Industry: Pharmaceuticals: other
Country: United States
Details
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.